3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
32
Myelodysplastic Syndromes
30
Leukemia, Myeloid, Acute
30
Multiple Myeloma
24
Lymphoma, Non-Hodgkin
24
Hodgkin Disease
24
Lymphoma
21
Leukemia
21
Graft vs Host Disease
21
Leukemia, Lymphocytic, Chronic, B-Cell
20
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Myeloproliferative Disorders
15
Lymphoma, Mantle-Cell
15
Neoplasms
14
Tuberous Sclerosis
13
Lymphoma, Large B-Cell, Diffuse
13
Hematologic Neoplasms
12
Burkitt Lymphoma
12
Primary Myelofibrosis
11
Lymphoma, Follicular
11
Breast Neoplasms
11
Waldenstrom Macroglobulinemia
10
Sarcoma
10
Recurrence
10
Neoplasms, Plasma Cell
10
Neoplasm Metastasis
10
Lymphoma, B-Cell, Marginal Zone
10
Leukemia, Myelomonocytic, Chronic
10
Prostatic Neoplasms
9
Lymphangioleiomyomatosis
9
Interventions
Carboplatin
88
pembrolizumab
85
Paclitaxel
71
Cyclophosphamide
63
Capecitabine
38
Doxorubicin
37
Taxes
29
130-nm albumin-bound paclitaxel
29
Cisplatin
25
Albumin-Bound Paclitaxel
22
Epirubicin
21
Drug Therapy
21
Docetaxel
20
sacituzumab govitecan
19
olaparib
19
camrelizumab
18
atezolizumab
18
Gemcitabine
17
eribulin
16
durvalumab
16
Bevacizumab
16
Radiotherapy
15
toripalimab
14
Specimen Handling
14
Biopsy
13
Everolimus
12
Magnetic Resonance Spectroscopy
11
apatinib
10
Nivolumab
10
talazoparib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Triple Negative Breast Neoplasms
×
Sirolimus
×
Clear all
NCT03805399
2022-08-10
FUTURE
Fudan University
Phase 1/2
Unknown
140 enrolled